Latigo Biotherapeutics, Inc. (LTGO) has 7 SEC Form 4 insider filings on record in the last 90 days. That includes 2 insider purchases totalling $5.0M. Most recent filing: Aug. 12, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Aug. 12, 2026 filed Aug. 10, 2026 | 5AM Ventures VI, L.P. 10% Owner | $0 | 14,651,924 | — | No | |
|
|
||||||
| Aug. 12, 2026 filed Aug. 10, 2026 | Sanofi 10% Owner | $0 | 1,345,556 | — | No | |
|
|
||||||
| Aug. 11, 2026 filed Aug. 10, 2026 | Westlake BioPartners Fund I, L.P. 10% Owner | $0 | 25,390,610 | — | No | |
|
|
||||||
| Aug. 10, 2026 | Foresite Capital Management V, LLC 10% Owner | +$2,520,000 | 18,222,656 | — | No | |
|
|
||||||
| Aug. 10, 2026 | Tananbaum James B. Director | +$2,520,000 | 18,222,656 | — | No | |
|
|
||||||
Showing the 5 most recent of 7 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free